Oculis Publishes Invitation to the Annual General Meeting
Oculis Holding AG (Nasdaq: OCS) has announced its 2025 Annual General Meeting, scheduled for June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland. The meeting will take place at 3:00 p.m. CEST / 9:00 a.m. EDT and will be held both in-person and via broadcast.
Prior to the AGM, the company will host a virtual information session on May 19, 2025 from 4:00 to 5:00 p.m. CEST, where management will present the meeting proposals and address shareholder questions. Meeting materials and webcast replay will be available on the Oculis website.
Oculis Holding AG (Nasdaq: OCS) ha annunciato la sua Assemblea Generale Annuale 2025, prevista per il 4 giugno 2025 presso Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Svizzera. La riunione si terrà alle 15:00 CEST / 9:00 EDT e sarà disponibile sia in presenza che in diretta streaming.
Prima dell'Assemblea, l'azienda organizzerà una sessione informativa virtuale il 19 maggio 2025 dalle 16:00 alle 17:00 CEST, durante la quale il management presenterà le proposte all'ordine del giorno e risponderà alle domande degli azionisti. I materiali della riunione e la registrazione della diretta saranno disponibili sul sito web di Oculis.
Oculis Holding AG (Nasdaq: OCS) ha anunciado su Junta General Anual 2025, programada para el 4 de junio de 2025 en Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Suiza. La reunión se llevará a cabo a las 3:00 p.m. CEST / 9:00 a.m. EDT y será presencial y transmitida en directo.
Antes de la Junta, la compañía realizará una sesión informativa virtual el 19 de mayo de 2025 de 4:00 a 5:00 p.m. CEST, donde la dirección presentará las propuestas de la reunión y responderá preguntas de los accionistas. Los materiales de la reunión y la repetición de la transmisión estarán disponibles en el sitio web de Oculis.
Oculis Holding AG (나스닥: OCS)는 2025년 정기 주주총회를 2025년 6월 4일 스위스 취리히 CH-6300 Zug, Kolinplatz 11, Ochsen-Zug에서 개최할 예정입니다. 회의는 오후 3시 CEST / 오전 9시 EDT에 현장 및 온라인 방송으로 진행됩니다.
주주총회 전에 회사는 2025년 5월 19일 오후 4시부터 5시까지 CEST 시간에 온라인 정보 세션을 개최하여 경영진이 회의 안건을 발표하고 주주들의 질문에 답변할 예정입니다. 회의 자료와 웹캐스트 재방송은 Oculis 웹사이트에서 확인할 수 있습니다.
Oculis Holding AG (Nasdaq : OCS) a annoncé son Assemblée Générale Annuelle 2025, prévue le 4 juin 2025 à Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Suisse. La réunion se tiendra à 15h00 CEST / 9h00 EDT, en présentiel et en diffusion en direct.
Avant l’Assemblée, la société organisera une session d’information virtuelle le 19 mai 2025 de 16h00 à 17h00 CEST, lors de laquelle la direction présentera les propositions à l’ordre du jour et répondra aux questions des actionnaires. Les documents de la réunion et le replay du webcast seront disponibles sur le site internet d’Oculis.
Oculis Holding AG (Nasdaq: OCS) hat seine Hauptversammlung 2025 für den 4. Juni 2025 angekündigt, die in Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Schweiz, stattfinden wird. Die Versammlung beginnt um 15:00 Uhr MESZ / 9:00 Uhr EDT und wird sowohl persönlich als auch per Übertragung abgehalten.
Vor der HV veranstaltet das Unternehmen am 19. Mai 2025 von 16:00 bis 17:00 Uhr MESZ eine virtuelle Informationsveranstaltung, bei der das Management die Tagesordnungspunkte vorstellt und Fragen der Aktionäre beantwortet. Die Sitzungsunterlagen und die Aufzeichnung der Übertragung werden auf der Oculis-Website verfügbar sein.
- None.
- None.
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here.
Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during which members of management will provide an overview of the 2025 Annual General Meeting proposals and answer questions from shareholders. To participate, please use the following link. The webcast of the virtual information session will be available following the event for replay and be accessible on the Oculis website here.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS / XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in clinical development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
FAQ
When is Oculis (OCS) 2025 Annual General Meeting?
Where will the Oculis 2025 AGM be held?
When is Oculis holding its virtual information session for shareholders?
How can shareholders access Oculis AGM materials?
